Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Bayer AG is a global life science company headquartered in Leverkusen, Germany, with a focus on healthcare and agriculture. It operates through three primary segments: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals segment develops and markets prescription medicines for cardiology, women's health, oncology, hematology, ophthalmology, and diagnostic imaging, including contrast agents and cell and gene therapies. Consumer Health offers over-the-counter medicines, medicated skincare, nutritional supplements, pain relief, cardiovascular risk prevention, digestive health, allergy, and cold and cough products. The Crop Science segment provides seeds, plant traits, crop protection products like pesticides, herbicides, and fungicides, along with digital solutions and services to support sustainable farming practices. Bayer AG serves healthcare professionals, patients, farmers, and consumers worldwide, playing a vital role in advancing medical treatments, everyday wellness, and agricultural productivity.
13.47% operating margin is respectable but not wide. ROIC at 7.17%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue declined 2.2% YoY. The question is whether this is cyclical or a structural shift.
Free cash flow declined 25% versus the prior year, cash generation momentum has weakened. Net debt of €28.60B represents 8.3x FCF, leverage limits flexibility.
Profitability & Returns
Revenue (TTM)
€45.24B
▼ -2.2% YoY
Net Income (TTM)
-€2.13B
▼ -41.2% YoY
Op. Margin
16.23%
▲ +6.3pp YoY
ROIC
7.17%
▲ +3.6pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
€2.64B
▼ -25.0% YoY
Op. Cash Flow (TTM)
€3.46B
▼ -35.1% YoY
Net Debt
€28.60B
Cash & Equiv.
€7.86B
3Y CAGR: -3.5%
3Y CAGR: -6.0%
Continue Research